BioSpace News Archive

Drug Development

Lilly’s GLP-1 Receptor Agonist Cuts Weight by Almost 15% in Mid-Stage Trial

New Phase II data, published in the New England Journal of Medicine, showed Lilly’s oral GLP-1 receptor agonist orforglipron induced nearly 15% weight loss in obese and overweight adults.

June 26, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Vertex Trial Data Show Two T1D Patients Reach Insulin Independence with Cell Therapy

A year after treatment, Vertex’s VX-880 has eliminated the need for insulin injections in two Type 1 diabetes patients in a Phase I/II clinical trial of its investigational stem cell-based therapy.

June 26, 2023
·
2 min read
·
Tristan Manalac
Pfizer Drops Early-Stage Obesity Drug Following Disappointing Phase I Data

The company is dropping its GLP-1 receptor agonist candidate lotiglipron after it induced elevations in liver enzymes in patients treated with the investigational drug.

June 26, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Second Strike for FibroGen’s Pamrevlumab—First Duchenne, Now Lung Fibrosis

FibroGen takes another hit as its antibody hopeful fails in a second indication. The biopharma says that it is cutting costs to extend its cash runway.

June 26, 2023
·
2 min read
·
Kate Goodwin
Deals

Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline

The acquisition of the privately-held company will bring its novel, investigational beta-lactamase inhibitors and other antimicrobials into the Japanese pharma’s pipeline.

June 26, 2023
·
2 min read
·
Connor Lynch
Drug Development

CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

CANbridge Pharmaceuticals, Inc. announced positive preliminary results from the ongoing Phase 1b study of omoprubart, a novel, long-acting, anti-C5 complement recombinant humanized monoclonal antibody, in paroxysmal nocturnal hemoglobinuria in China.

June 26, 2023
·
8 min read
Genetown

Emulate Unveils Chip-A1, Expanding Organ-on-a-Chip Technology Applications Within the Cancer and Cosmetics Markets

Emulate, Inc., the leading provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program.

June 26, 2023
·
5 min read
Business

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer

Immodulon, a late-stage clinical company developing a highly differentiated cancer immunotherapy that primes the patient’s own innate immune system, announces it has appointed Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer.

June 26, 2023
·
4 min read
Actimed Therapeutics closes over-subscribed Series A Financing Round of £5 million to advance clinical development of lead programme for cancer cachexia

Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that it has raised over £5 million in an over-subscribed Series A financing round.

June 26, 2023
·
3 min read
Pharm Country

HUTCHMED to Announce 2023 Half-Year Financial Results

HUTCHMED Limited will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00 am Eastern Daylight Time / 12:00 noon British Summer Time / 7:00 pm Hong Kong Time.

June 26, 2023
·
1 min read